Mitochondria and Redox Signaling in Steatohepatitis
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Alcoholic and nonalcoholic fatty liver diseases are potentially pathological conditions that can progress to steatohepatitis, fibrosis, and cirrhosis. These conditions affect millions of people throughout the world in part through poor lifestyle choices of excess alcohol consumption, overnutrition, and lack of regular physical activity. Abnormal mitochondrial and cellular redox homeostasis has been documented in steatohepatitis and results in alterations of multiple redox-sensitive signaling cascades. Ultimately, these changes in signaling lead to altered enzyme function and transcriptional activities of proteins critical to mitochondrial and cellular function. In this article, we review the current hypotheses linking mitochondrial redox state to the overall pathophysiology of alcoholic and nonalcoholic steatohepatitis and briefly discuss the current therapeutic options under investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“With the current safety issues regarding long-term TZD therapy (146), the usefulness of this agent in the treatment of steatohepatitis is questionable.”
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“Importantly, human stable isotope studies have documented the involvement of increased de novo lipogenesis in the development of FLD (46, 47).”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“Several human trials have observed improvement in steatosis and liver histology in steatohepatitis after TZD therapy alone or in conjunction with other treatment modalities (2, 14, 142, 171, 186).”
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 1×
“Several human trials have observed improvement in steatosis and liver histology in steatohepatitis after TZD therapy alone or in conjunction with other treatment modalities (2, 14, 142, 171, 186).”
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“abnormalities may be involved in NAFLD (13, 21, 54, 91, 144, 162, 185).”
Mitochondria, oxygen free radicals, disease and ageing
Raha, S., & Robinson, B. H. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01674-1 · Cited by 1,066 · cited 2×
“This ROS production occurs through reduction of molecular oxygen to superoxide (O2 - ) by Complex I and III of the ETC (9, 109, 147, 166, 230) (Fig.”
Peroxisomes and oxidative stress
Schrader, M., & Fahimi, H. D. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.09.006 · Cited by 838
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753 · cited 5×
“This can be observed under conditions of increased b -oxidation of FFAs in NASH (13) and elevated mitochondrial NADH due to alcohol metabolism in ASH (165).”
InfluentialDefective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis.
Pérez-Carreras, M., Del Hoyo, P., Martín, M. A., Rubio, J. C., Martín, A., Castellano, G., Colina, F., Arenas, J., & Solis-Herruzo, J. A. (2003) · Hepatology · doi:10.1002/hep.1840380426 · Cited by 734 · cited 3×
“The activities in all five complexes of oxidative phosphorylation have been observed to be lower in subjects with NASH (83, 157).”
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721 · cited 3×
“The beta-oxidation of acyl-CoAs requires four enzymatic reactions: dehydrogenation by acyl-CoA dehydrogenase (AD), hydration by enoyl-CoA hydratase (2), oxidation by L-b-hydroxyacylCoA dehydrogenase (3), and thiolysis by b-ketothiolase(4).”
Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle
Winder, W. W., Holmes, B. F., Rubink, D. S., Jensen, E. B., Chen, M., & Holloszy, J. O. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.6.2219 · Cited by 709 · cited 1×
“Metformin can activate AMPK in liver (234) and this activation can result in increased CPT-1 activity and increased expression of proteins involved in mitochondrial respiration (218).”
Metformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G., & Diehl, A. M. (2000) · Nature Medicine · doi:10.1038/79697 · Cited by 673
Cardiovascular risk factors emerge after artificial selection for low aerobic capacity.
Wisløff, U., Najjar, S. M., Ellingsen, Ø., Haram, P. M., Swoap, S., Al-Share, Q., Fernström, M., Rezaei, K., Lee, S. J., Koch, L. G., et al. (2005) · Science · doi:10.1126/science.1108177 · Cited by 657
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 1×
“Several human trials have observed improvement in steatosis and liver histology in steatohepatitis after TZD therapy alone or in conjunction with other treatment modalities (2, 14, 142, 171, 186).”
A signalling role for 4‐hydroxy‐2‐nonenal in regulation of mitochondrial uncoupling
Echtay, K. S., Esteves, T. C., Pakay, J. L., Jekabsons, M. B., Lambert, A. J., Portero‐Otín, M., Pamplona, R., Vidal‐Puig, A. J., Wang, S., Roebuck, S. J., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg412 · Cited by 597
Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1
Gonzalez, F. J. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.04.021 · Cited by 555 · cited 1×
“These observed increases in cytochrome P450 activity make it an important source of ROS in hepatocytes under pathophysiological conditions (31, 75, 188).”
Alcohol and mitochondria: a dysfunctional relationship
Hoek, J. B., Cahill, A., & Pastorino, J. G. (2002) · Gastroenterology · doi:10.1053/gast.2002.33613 · Cited by 553 · cited 7×
“Finally, an additive effect of ethanol-induced reductions in mtDNA and increased susceptibility to ethanol-induced MPT activation and apoptosis may exist in chronic alcohol consumption (86).”
InfluentialMahadev, K., Zilbering, A., Zhu, L., & Goldstein, B. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100109200 · Cited by 509
Central Role of Pparα–Dependent Hepatic Lipid Turnover in Dietary Steatohepatitis in Mice
Ip, E., Farrell, G. C., Robertson, G., Hall, P., Kirsch, R., & Leclercq, I. (2003) · Hepatology · doi:10.1053/jhep.2003.50307 · Cited by 476 · cited 1×
“Additional studies utilizing pharmaceutical PPARa agonists have also described improvement in steatosis potentially through the increased expression of enzymes involved in lipid oxidation, and decreased fibrosis in a rodent model of NASH (92, 93, 169).”
The role of AMP-activated protein kinase in the action of ethanol in the liver
You, M., Matsumoto, M., Pacold, C. M., Cho, W. K., & Crabb, D. W. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.049 · Cited by 469
Pessayre, D., & Fromenty, B. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.03.004 · Cited by 441 · cited 1×
“abnormalities may be involved in NAFLD (13, 21, 54, 91, 144, 162, 185).”
Ip, E., Farrell, G., Hall, P., Robertson, G., & Leclercq, I. (2004) · Hepatology · doi:10.1002/hep.20170 · Cited by 383
Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease
Zakhari, S., & Li, T.-K. (2007) · Hepatology · doi:10.1002/hep.22010 · Cited by 333 · cited 4×
“The LCR rats display a higher incidence of both CVD and metabolic syndrome risk factors than HCR rats.”
InfluentialRector, R. S., Thyfault, J. P., Morris, R. T., Laye, M. J., Borengasser, S. J., Booth, F. W., & Ibdah, J. A. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00428.2007 · Cited by 321 · cited 1×
“Moreover, our recent findings in the OLETF and the HCR/LCR rodent models further support daily exercise and increased aerobic fitness in the protection from development of NAFLD and the importance of hepatic mitochondrial content and function in this process (173, 174, 206).”
Self-citationHabitual Physical Activity Is Associated With Intrahepatic Fat Content in Humans
Perseghin, G., Lattuada, G., De Cobelli, F., Ragogna, F., Ntali, G., Esposito, A., Belloni, E., Canu, T., Terruzzi, I., Scifo, P., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2032 · Cited by 320
Independent effects of physical activity in patients with nonalcoholic fatty liver disease #
St. George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., & George, J. (2009) · Hepatology · doi:10.1002/hep.22940 · Cited by 318
Molecular Mechanisms of Alcoholic Fatty Liver
Purohit, V., Gao, B., & Song, B. (2009) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00827.x · Cited by 312
Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study
Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Zvibel, I., Goldiner, I., Blendis, L., Halpern, Z., & Oren, R. (2008) · Hepatology · doi:10.1002/hep.22525 · Cited by 296
Increased Hepatic Myeloperoxidase Activity in Obese Subjects with Nonalcoholic Steatohepatitis
Rensen, S. S., Slaats, Y., Nijhuis, J., Jans, A., Bieghs, V., Driessen, A., Malle, E., Greve, J. W., & Buurman, W. A. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080999 · Cited by 290
Church, T. S., Kuk, J. L., Ross, R., Priest, E. L., Biltoff, E., & Blair, S. N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.019 · Cited by 268 · cited 3×
“We have generated a mouse model for a null In our second series of studies, we have characterized the natural progression of NAFLD and NASH in the OLETF rat, a hyperphagic, obese, rodent model (175) that we liken to overweight, overeating, sedentary humans.”
High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo
Mantena, S. K., Vaughn, D. P., Andringa, K. K., Eccleston, H. B., King, A. L., Abrams, G. A., Doeller, J. E., Kraus, D. W., Darley-Usmar, V. M., & Bailey, S. M. (2009) · Biochemical Journal · doi:10.1042/bj20080868 · Cited by 265 · cited 1×
“Also, lower cytochrome c oxidase and mitochondrial membrane potentials were observed in mice that developed NAFLD after high-fat diet feeding (126).”
Intracellular generation of reactive oxygen species by mitochondria
Nohl, H., Gille, L., & Staniek, K. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.12.002 · Cited by 251 · cited 2×
“This ROS production occurs through reduction of molecular oxygen to superoxide (O2 - ) by Complex I and III of the ETC (9, 109, 147, 166, 230) (Fig.”
Fujita, K., Nozaki, Y., Wada, K., Yoneda, M., Fujimoto, Y., Fujitake, M., Endo, H., Takahashi, H., Inamori, M., Kobayashi, N., et al. (2009) · Hepatology · doi:10.1002/hep.23094 · Cited by 244
Role of insulin-induced reactive oxygen species in the insulin signaling pathway
Goldstein, B. J., Mahadev, K., Wu, X., Zhu, L., & Motoshima, H. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1021 · Cited by 238
Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling
Schattenberg, J. M., Wang, Y., Singh, R., Rigoli, R. M., & Czaja, M. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410310200 · Cited by 194 · cited 1×
“These observed increases in cytochrome P450 activity make it an important source of ROS in hepatocytes under pathophysiological conditions (31, 75, 188).”
Nonalcoholic fatty liver disease
Erickson, S. K. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800089-jlr200 · Cited by 194
Ibdah, J. A., Perlegas, P., Zhao, Y., Angdisen, J., Borgerink, H., Shadoan, M. K., Wagner, J. D., Matern, D., Rinaldo, P., & Cline, J. M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.02.001 · Cited by 186
Self-citationLack of mitochondrial trifunctional protein in mice causes neonatal hypoglycemia and sudden death
Ibdah, J. A., Paul, H., Zhao, Y., Binford, S., Salleng, K., Cline, M., Matern, D., Bennett, M. J., Rinaldo, P., & Strauss, A. W. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12590 · Cited by 181
Self-citationHealth‐related fitness and physical activity in patients with nonalcoholic fatty liver disease†‡
Krasnoff, J. B., Painter, P. L., Wallace, J. P., Bass, N. M., & Merriman, R. B. (2008) · Hepatology · doi:10.1002/hep.22137 · Cited by 148 · cited 3×
“We have generated a mouse model for a null In our second series of studies, we have characterized the natural progression of NAFLD and NASH in the OLETF rat, a hyperphagic, obese, rodent model (175) that we liken to overweight, overeating, sedentary humans.”
Young, T. A., Cunningham, C. C., & Bailey, S. M. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00338-7 · Cited by 128 · cited 2×
“This ROS production occurs through reduction of molecular oxygen to superoxide (O2 - ) by Complex I and III of the ETC (9, 109, 147, 166, 230) (Fig.”
Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats
Moon, K.-H., Hood, B. L., Kim, B.-J., Hardwick, J. P., Conrads, T. P., Veenstra, T. D., & Song, B. J. (2006) · Hepatology · doi:10.1002/hep.21372 · Cited by 120
Rector, R. S., Thyfault, J. P., Laye, M. J., Morris, R. T., Borengasser, S. J., Uptergrove, G. M., Chakravarthy, M. V., Booth, F. W., & Ibdah, J. A. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2008.156745 · Cited by 110 · cited 4×
“Recently, our group has reported elevated levels of several of these enzymes and transcription factors in a rodent model that spontaneously develops NASH (173, 175).”
InfluentialSelf-citationNiemelä, O., Parkkila, S., Pasanen, M., Limuro, Y., Bradford, B., & Thurman, R. G. (1998) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1998.tb05925.x · Cited by 107
Rubinstein, E., Lavine, J., & Schwimmer, J. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091982 · Cited by 60
Cited by
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Mitochondrial alterations in fatty liver diseases
Fromenty, B., & Roden, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.020 · Cited by 424
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Free radical biology for medicine: learning from nonalcoholic fatty liver disease
Serviddio, G., Bellanti, F., & Vendemiale, G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.174 · Cited by 267
β-Catenin Regulates Hepatic Mitochondrial Function and Energy Balance in Mice
Lehwald, N., Tao, G., Jang, K. Y., Papandreou, I., Liu, B., Liu, B., Pysz, M. A., Willmann, J. K., Knoefel, W. T., Denko, N. C., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.048 · Cited by 102
Metadata
- Authors
- Morris, E. M., Rector, R. S., Thyfault, J. P., & Ibdah, J. A.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2011-07-15
- Volume
- 15
- Issue
- 2
- Pages
- 485-504
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W1965661560
- Cited by
- 72
- References
- 49
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.